I'll save them for the dark days. I have to agree with Robert that we can never get away from the need to take a good hard look at the patient. After all, we've been doing just that for years. I would like to offer a couple of observations from my own experience 1. Adequete monitoring is not optimal monitoring.
Patient comfort is an important factor.
Baysian modeling allows me to do that better than anything else I've used so far. The major importance of PK Modeling is not treating the normal patient, but rather identifying the abnormal patient. I have several cases where seat of the pants monitoring was way off the mark simply because the patients were on the edges of the curves. Even decent linear regression software produces better results. In the past 15 yrs I've been involved in this, I seen less than 5 aminoglycoside toxicity patients total.